Zobrazeno 1 - 10
of 17
pro vyhledávání: '"Lindy Bancke"'
Autor:
Christine Lee, Thomas Louie, Lindy Bancke, Beth Guthmueller, Adam Harvey, Paul Feuerstadt, Sahil Khanna, Robert Orenstein, Erik R. Dubberke
Publikováno v:
Therapeutic Advances in Gastroenterology, Vol 16 (2023)
Background: Microbiota-based treatments reduce the incidence of recurrent Clostridioides difficile infections (rCDIs), but prospectively collected safety data needed to broaden patient access and protect public health have been limited. Objectives: W
Externí odkaz:
https://doaj.org/article/8cc4ae3fc160414a878b1f6287d6adf4
Autor:
Paul Feuerstadt, Adam Harvey, David S Yoho, Julia B Garcia-Diaz, Whitfield L Knapple, Lindy Bancke
Publikováno v:
Open Forum Infectious Diseases. 10
Background Fecal microbiota, live-jslm (RBL; REBYOTA™), the first microbiota-based live biotherapeutic approved by the US Food and Drug Administration to prevent recurrent Clostridioides difficile infection (rCDI) in adults, has been evaluated in 5
Autor:
Glenn Tillotson, Laurie Archbald-Pannone, Stuart Johnson, Samson Ng, Masakazu Ando, Adam Harvey, Lindy Bancke, Paul Feuerstadt
Publikováno v:
Open Forum Infectious Diseases. 10
Background Advanced age and underlying comorbidities are associated with greater rates of recurrence in patients with Clostridioides difficile infection (CDI). Reducing the likelihood of recurrence through treatment with an antimicrobial followed by
Autor:
Paul Feuerstadt, Erik R Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana García-Horton, Mirko Fillbrunn, Glenn S Tillotson, Lindy Bancke, Kevin W Garey
Publikováno v:
Open Forum Infectious Diseases. 9
Background Recurrence of Clostridioides difficile infection (rCDI) is common - up to 35% of patients may recur. RBX2660 is a microbiota restoration therapy to reduce rCDI. Here we report 8 weeks HRQL results using the Clostridioides difficile Health-
Autor:
Sahil Khanna, Maha Assi, Christine Lee, David Yoho, Thomas Louie, Whitfield Knapple, Humberto Aguilar, Julia Garcia-Diaz, Gary P. Wang, Scott M. Berry, Joe Marion, Xin Su, Tricia Braun, Lindy Bancke, Paul Feuerstadt
Publikováno v:
DrugsReferences. 82(15)
Recurrent Clostridioides difficile infection, associated with dysbiosis of gut microbiota, has substantial disease burden in the USA. RBX2660 is a live biotherapeutic product consisting of a broad consortium of microbes prepared from human stool that
Autor:
Paul Feuerstadt, Erik R. Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana Garcia-Horton, Mirko Fillbrunn, Jonathan Salcedo, Glenn Tillotson, Lindy Bancke, Kevin W. Garey
Publikováno v:
American Journal of Gastroenterology. 117:e604-e605
Autor:
Paul Feuerstadt, Erik R. Dubberke, Amy Guo, Adam Harvey, Min Yang, Viviana Garcia-Horton, Mirko Fillbrunn, Jonathan Salcedo, Glenn Tillotson, Lindy Bancke, Kevin W. Garey
Publikováno v:
American Journal of Gastroenterology. 117:e606-e606
Autor:
Sahil Khanna, Maha Assi, Christine Lee, David Yoho, Thomas Louie, Whitfield Knapple, Humberto Aguilar, Julia Garcia-Diaz, Gary P. Wang, Scott M. Berry, Joe Marion, Xin Su, Tricia Braun, Lindy Bancke, Paul Feuerstadt
Publikováno v:
Drugs. 82:1539-1539
Autor:
Sahil Khanna, Glenn Tillotson, Masakazu Ando, Lindy Bancke, Adam Harvey, Kevin W. Garey, Kerry LaPlante
Publikováno v:
American Journal of Gastroenterology. 117:e138-e138
Autor:
Lindy Bancke, Xin Su
Publikováno v:
Open Forum Infectious Diseases
Background Microbiota-based treatments have shown promise to reduce recurrence, morbidity, and mortality for recurrent Clostridioides difficile infections (rCDI), but consistent and reliable clinical efficacy data are needed to support regulatory app